Basel Medical Group (NASDAQ:BMGL – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.31) earnings per share for the quarter, reports. The firm had revenue of $3.14 million for the quarter.
Basel Medical Group Price Performance
BMGL opened at $5.04 on Friday. Basel Medical Group has a 12-month low of $2.56 and a 12-month high of $18.72. The business’s fifty day simple moving average is $4.37 and its 200-day simple moving average is $6.51.
Wall Street Analyst Weigh In
Separately, Weiss Ratings cut shares of Basel Medical Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 23rd. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Basel Medical Group has a consensus rating of “Sell”.
Get Our Latest Report on Basel Medical Group
About Basel Medical Group
Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.
Further Reading
- Five stocks we like better than Basel Medical Group
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
Receive News & Ratings for Basel Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basel Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
